Morgan Stanley
SPRY icon

Morgan Stanley’s ARS Pharmaceuticals SPRY Stock Holding History

Morgan Stanley’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
229,100
-87,573
-28% -$753K ﹤0.01% 4898
2026
Q1 		$2.54M Sell
316,673
-235,691
-43% -$2.26M ﹤0.01% 4593
2025
Q4 		$6.44M Sell
552,364
-148,050
-21% -$1.44M ﹤0.01% 3989
2025
Q3 		$7.04M Buy
700,414
+316,798
+83% +$4.55M ﹤0.01% 3865
2025
Q2 		$6.69M Sell
383,616
-58,898
-13% -$850K ﹤0.01% 3811
2025
Q1 		$5.57M Buy
442,514
+9,911
+2% +$119K ﹤0.01% 3844
2024
Q4 		$4.56M Sell
432,603
-206,019
-32% -$2.89M ﹤0.01% 4076
2024
Q3 		$9.26M Buy
638,622
+504,816
+377% +$6M ﹤0.01% 3485
2024
Q2 		$1.14M Buy
133,806
+35,853
+37% +$318K ﹤0.01% 4883
2024
Q1 		$1M Sell
97,953
-9,960
-9% -$74.3K ﹤0.01% 4954
2023
Q4 		$591K Buy
107,913
+23,700
+28% +$104K ﹤0.01% 5223
2023
Q3 		$318K Buy
84,213
+23,534
+39% +$154K ﹤0.01% 5371
2023
Q2 		$407K Sell
60,679
-38,927
-39% -$260K ﹤0.01% 5315
2023
Q1 		$648K Buy
99,606
+10,392
+12% +$79.8K ﹤0.01% 5108
2022
Q4 		$761K Buy
89,214
+33,119
+59% +$215K ﹤0.01% 5016
2022
Q3 		$295K Sell
56,095
-181,512
-76% -$894K ﹤0.01% 5543
2022
Q2 		$1.01M Sell
237,607
-148,340
-38% -$517K ﹤0.01% 5010
2022
Q1 		$1.35M Sell
385,947
-1,004,963
-72% -$4.38M ﹤0.01% 4784
2021
Q4 		$9.26M Buy
1,390,910
+752,209
+118% +$6.11M ﹤0.01% 3024
2021
Q3 		$6.37M Buy
638,701
+625,477
+4,730% +$15.4M ﹤0.01% 3422
2021
Q2 		$408K Buy
+13,224
New +$424K ﹤0.01% 5652
2021
Q1 		– Sell
-2,365
Closed -$110K – 7554
2020
Q4 		$110K Buy
+2,365
New +$79K ﹤0.01% 5868

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley's SPRY Position: Q2 2026 in Review

Morgan Stanley reduced its ARS Pharmaceuticals (SPRY) stake by 28% in Q2 2026, selling an estimated $753K and leaving 229,100 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4898.

Morgan Stanley first reported a position in SPRY in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.26M in Q4 2021. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Morgan Stanley held 229,100 shares of ARS Pharmaceuticals worth $1.84M as of Q2 2026.
  • Morgan Stanley sold 87,573 ARS Pharmaceuticals shares in Q2 2026, an estimated $753K.
  • ARS Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4898 holding.
  • Morgan Stanley first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Morgan Stanley's ARS Pharmaceuticals position peaked at $9.26M in Q4 2021.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.